LATEST NEWS

6.13.19 - TERNS PHARMACEUTICALS INITIATES A PHASE 1 CLINICAL TRIAL OF TERN-101. READ MORE

 
logo-wood-backdrop.jpg

POSTERS & PRESENTATIONS

TERNS 101

A novel farnesoid X receptor agonist, TERN-101, reduces liver steatosis, inflammation, ballooning and fibrosis in a murine model of non-alcoholic steatohepatitis

TERNS 201

A novel semicarbazide-sensitive amine oxidase inhibitor, TERN-201, reduces NAS and fibrosis in rodent models of non-alcoholic steatohepatitis


UPCOMING PRESENTATIONS

There are currently no upcoming presentations.


PAST PRESENTATIONS

There are currently no past presentations.

mgmt-background.jpg